Phase II Randomized Trial of MEK Inhibitor MSC1936369B or Placebo Combined With Gemcitabine in Metastatic Pancreas Cancer Subjects
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006676/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The research trial is testing the experimental treatment MSC1936369B in combination with
Gemcitabine, in subjects with metastatic pancreatic adenocarcinoma. The study will be run in
two parts:
Safety Run-In: Will determine the Maximum Tolerated Dose (MTD) and the recommended Phase II
dose of MSC1936369B, when combined with gemcitabine, in subjects with metastatic pancreatic
adenocarcinoma.
Phase II: Will assess the anti-tumor activity of MSC1936369B combined with gemcitabine
compared to gemcitabine alone as first line treatment in subjects with metastatic pancreatic
adenocarcinoma.
提供机构：
Vivli
创建时间：
2021-02-09
